78.13
-0.19 (-0.24%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Intra-Cellular Therapies Inc. | Bearish | Bullish |
Stockmoo Score
|
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 130.00 (Cantor Fitzgerald, 66.39%) | Buy |
| Median | 100.00 (27.99%) | |
| Low | 74.00 (Goldman Sachs, -5.29%) | Hold |
| Average | 97.22 (24.43%) | |
| Total | 7 Buy, 2 Hold | |
| Avg. Price @ Call | 74.79 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 06 Sep 2024 | 92.00 (17.75%) | Buy | 73.20 |
| JP Morgan | 21 Aug 2024 | 81.00 (3.67%) | Buy | 75.69 |
| 12 Jun 2024 | 78.00 (-0.17%) | Buy | 68.20 | |
| Cantor Fitzgerald | 08 Aug 2024 | 130.00 (66.39%) | Buy | 74.42 |
| 14 Jun 2024 | 120.00 (53.59%) | Buy | 67.77 | |
| Goldman Sachs | 08 Aug 2024 | 74.00 (-5.29%) | Hold | 74.42 |
| Needham | 08 Aug 2024 | 100.00 (27.99%) | Buy | 74.42 |
| 22 Jul 2024 | 100.00 (27.99%) | Buy | 76.48 | |
| RBC Capital | 08 Aug 2024 | 106.00 (35.67%) | Buy | 74.42 |
| 25 Jun 2024 | 103.00 (31.83%) | Buy | 72.42 | |
| UBS | 08 Aug 2024 | 79.00 (1.11%) | Hold | 74.42 |
| 25 Jun 2024 | 83.00 (6.23%) | Hold | 72.42 | |
| Mizuho | 21 Jun 2024 | 100.00 (27.99%) | Buy | 76.58 |
| Canaccord Genuity | 20 Jun 2024 | 113.00 (44.63%) | Buy | 75.55 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MATES SHARON | - | 73.71 | -95,925 | -7,064,498 |
| Aggregate Net Quantity | -95,925 | |||
| Aggregate Net Value ($) | -7,064,498 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 73.71 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MATES SHARON | Officer | 28 Aug 2024 | Automatic sell (-) | 32,699 | 72.77 | 2,379,506 |
| MATES SHARON | Officer | 28 Aug 2024 | Option execute | 32,699 | - | - |
| MATES SHARON | Officer | 27 Aug 2024 | Automatic sell (-) | 40,513 | 73.88 | 2,993,100 |
| MATES SHARON | Officer | 27 Aug 2024 | Option execute | 40,513 | - | - |
| MATES SHARON | Officer | 26 Aug 2024 | Automatic sell (-) | 22,713 | 74.49 | 1,691,891 |
| MATES SHARON | Officer | 26 Aug 2024 | Option execute | 22,713 | - | - |
| Date | Type | Details |
|---|---|---|
| 28 Aug 2024 | Announcement | Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences |
| 08 Aug 2024 | Announcement | Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference |
| 07 Aug 2024 | Announcement | Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer |
| 07 Aug 2024 | Announcement | Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance |
| 24 Jul 2024 | Announcement | Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast |
| 18 Jun 2024 | Announcement | Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder |
| 10 Jun 2024 | Announcement | Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |